Journal
NATURE MEDICINE
Volume 21, Issue 3, Pages 231-+Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nm.3799
Keywords
-
Funding
- US National Institutes of Health/National Cancer Institute [R01CA160331, R01CA163377, T32CA9171-35]
- US Department of Defense Ovarian Cancer Academy award [OC093420]
- Ovarian Cancer Research Fund Program project
- Ovarian Cancer Research Fund Liz Tilberis Scholar
- American Cancer Society postdoctoral fellowship [PF-13-058-01-TBE]
- Cancer Center [CA010815]
- CDMRP [OC093420, 546100] Funding Source: Federal RePORTER
Ask authors/readers for more resources
The gene encoding ARID1A, a chromatin remodeler, shows one of the highest mutation rates across many cancer types. Notably, ARID1A is mutated in over 50% of ovarian clear cell carcinomas, which currently have no effective therapy. To date, clinically applicable targeted cancer therapy based on ARID1A mutational status has not been described. Here we show that inhibition of the EZH2 methyltransferase acts in a synthetic lethal manner in ARID1A-mutated ovarian cancer cells and that ARID1A mutational status correlated with response to the EZH2 inhibitor. We identified PIK3IP1 as a direct target of ARID1A and EZH2 that is upregulated by EZH2 inhibition and contributed to the observed synthetic lethality by inhibiting PI3K-AKT signaling. Importantly, EZH2 inhibition caused regression of ARID1A-mutated ovarian tumors in vivo. To our knowledge, this is the first data set to demonstrate a synthetic lethality between ARID1A mutation and EZH2 inhibition. Our data indicate that pharmacological inhibition of EZH2 represents a novel treatment strategy for cancers involving ARID1A mutations.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available